Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
Citigroup Private Bank Appoints Chad Reddy as West Market Executive in North America 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Texas Attorney General Ken Paxton Sues Sanofi Over Alleged Healthcare Bribery Scheme 
Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Freedom Finance and Binance Join Forces in Digital Assets 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Heidelberg, Germany, May 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on May 15, 2018, the Company will release its financial results for the quarter ended March 31, 2018. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, May 15, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3326332.
United States: +1 720-543-0214
Germany: +49 (0)89 20303 5709
Netherlands: +31 (0) 20 721 9251
Denmark: +45 35 15 80 49
France: +33 (0)1 76 77 22 74
Switzerland: +41 (0)22 567 5729
United Kingdom: +44 (0)330 336 9105
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
